Theravance Biopharma (TBPH) Cash from Operations Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 158.60% |
| 10 | Theravance Biopharma | 866.36 Mn | 471.69 Mn | - | 70.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.26% |
| Dec 31, 2025 | -572.28% |
| Sep 30, 2025 | -25.25% |
| Jun 30, 2025 | 4,812.89% |
| Mar 31, 2025 | 4,311.25% |
| Dec 31, 2024 | -5.62% |
| Sep 30, 2024 | -109.01% |
| Jun 30, 2024 | 64.50% |
| Mar 31, 2024 | 90.89% |
| Dec 31, 2023 | -101.56% |
| Sep 30, 2023 | 84.97% |
| Jun 30, 2023 | 15.57% |
| Mar 31, 2023 | 56.96% |
| Dec 31, 2022 | 229.41% |
| Sep 30, 2022 | 63.61% |
| Jun 30, 2022 | 70.61% |
| Mar 31, 2022 | 62.69% |
| Dec 31, 2021 | 34.64% |
| Sep 30, 2021 | 41.00% |
| Jun 30, 2021 | 6.06% |